Loading...
•
Dec 31, 2023
Nkarta Q4 2023 Earnings Report
Nkarta reported financial results for the fourth quarter and year ended December 31, 2023.
Key Takeaways
Nkarta's pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX101. The company had $250.9 million in cash, cash equivalents and investments as of year-end 2023, which is anticipated to fund operations into 2026.
First patient dosing on track for first half of 2024 in clinical trial of NKX019 in lupus nephritis using disease-tailored lymphodepletion
Additional B-cell mediated autoimmune diseases under consideration for broader clinical investigation of NKX019
Pipeline realignment focuses resources on rapid advancement of NKX019 in autoimmune diseases and deprioritizes development of NKX101
2023 year-end cash, cash equivalents and investments of $250.9 million
Forward Guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...